Kevin Comcowich - 10 Sep 2026 Form 4 Insider Report for Arcadia Biosciences, Inc. (RKDA)

Reporting relationship: Director
Issuer ticker: RKDA
Reported as of: 10 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Sep 2026, 16:03:10 UTC
Prior SEC filing: 21 Aug 2024
Source filing: View source filing
Reporting owner signature: Kevin Comcowich, by Attorney-in-fact, Solaeta Chan

Key filing fact

Kevin Comcowich filed Form 4 for Arcadia Biosciences, Inc. (RKDA) on 14 Sep 2026.

Key facts

This page summarizes Kevin Comcowich's Form 4 filing for Arcadia Biosciences, Inc. (RKDA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Sep 2026, 16:03.

Change

Previous filing in this sequence was filed on 21 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001688770 Primary reporting owner

Comcowich Kevin

Relationship: Director
Address: C/O ARCADIA BIOSCIENCES, INC., 5956 SHERRY LANE, SUITE 2000, DALLAS
Signature: Kevin Comcowich, by Attorney-in-fact, Solaeta Chan
Signature date: 14 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RKDA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +23,000
Change %: +74%
Price: $0.000000^*
Shares after: 54,042
Date: 10 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,000
Exercise price: $0.4600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.